Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Myomo, Inc. MYO

Healthcare  —  Medical Devices
1.61 (0.06) (3.59%) as of 25 Sep
Market cap
$64.6M
P/E
0.0×
Revenue Champion (10y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Myomo, Inc. (MYO) Business Profile

Updated before January 2025

Company Overview

Myomo, Inc. (MYO) is a leading medical robotics company specializing in the development and commercialization of wearable robotic devices designed to restore mobility to individuals with neuromuscular impairments. Founded in 2004, Myomo emerged from research conducted at the Massachusetts Institute of Technology (MIT) in collaboration with Harvard Medical School. The company is headquartered in Cambridge, Massachusetts, and has established itself as a pioneer in the field of assistive technology.

The leadership team at Myomo is composed of experienced professionals with expertise in medical devices, robotics, and healthcare. Paul R. Gudonis serves as the Chairman and Chief Executive Officer (CEO), bringing decades of experience in technology and healthcare innovation. The company’s leadership is committed to advancing the field of medical robotics and improving the quality of life for individuals with mobility challenges.

Core Business Segments

Myomo focuses on the development and commercialization of advanced robotic orthoses. The company’s flagship product is the MyoPro® line of powered orthotic devices. These devices are designed to assist individuals with upper limb paralysis or weakness due to conditions such as stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, or brachial plexus injury. Below are the major product categories:

MyoPro® Orthotic Devices

  1. MyoPro® Control Systems: These systems use advanced sensors and algorithms to detect weak muscle signals in the user’s arm. The device then amplifies these signals to enable movement, allowing users to perform daily tasks such as eating, dressing, and grooming.

  2. MyoPro® Custom-Fit Devices: Myomo offers custom-fit solutions tailored to the unique needs of each patient. These devices are designed to maximize comfort and functionality, ensuring optimal performance for users.

  3. MyoPro® for Pediatric Use: Recognizing the need for assistive technology for younger patients, Myomo has developed pediatric versions of its MyoPro® devices. These products are specifically designed to accommodate the smaller anatomy and unique needs of children.

  4. MyoPro® Direct-to-Consumer Program: Myomo has implemented a direct-to-consumer model, allowing patients to access its products without relying solely on traditional healthcare channels. This program includes telehealth consultations, insurance verification, and device fitting services.

Business Model

Myomo operates on a hybrid business model that integrates product sales, service offerings, and reimbursement from insurance providers. The company generates revenue through the following channels:

  1. Product Sales: Myomo sells its MyoPro® devices directly to patients, healthcare providers, and rehabilitation centers. The company also partners with orthotics and prosthetics (O&P) clinics to expand its reach.

  2. Reimbursement: A significant portion of Myomo’s revenue comes from insurance reimbursements. The company works closely with private insurers, Medicare, and Medicaid to ensure coverage for its devices.

  3. Service Offerings: Myomo provides a range of services, including telehealth consultations, device fitting, and ongoing support. These services are designed to enhance the user experience and ensure the long-term success of its products.

  4. Licensing Agreements: Myomo has entered into licensing agreements with international partners to expand its presence in global markets. These agreements enable the company to leverage local expertise and infrastructure while maintaining control over its intellectual property.

Strategic Direction

Myomo is focused on expanding its market presence and driving innovation in the field of medical robotics. Key strategic initiatives include:

  1. Product Development: The company is investing in research and development to enhance the functionality and usability of its MyoPro® devices. Future product iterations may include improved sensors, lighter materials, and enhanced connectivity features.

  2. Global Expansion: Myomo is actively pursuing opportunities to expand its footprint in international markets. The company has established partnerships in Europe, Asia, and other regions to bring its products to a broader audience.

  3. Telehealth Integration: Recognizing the growing importance of telehealth, Myomo is integrating virtual consultations and remote monitoring capabilities into its service offerings. This approach aims to improve accessibility and convenience for patients.

  4. Sustainability Goals: Myomo is committed to sustainability and is exploring ways to reduce the environmental impact of its manufacturing processes. The company is also focused on developing durable, long-lasting products to minimize waste.

Competitive Landscape

Myomo operates in a competitive market that includes both established medical device companies and emerging startups. Key competitors include:

  1. Ottobock: A global leader in prosthetics and orthotics, Ottobock offers a range of advanced assistive devices, including robotic exoskeletons.

  2. Ekso Bionics: Specializing in wearable exoskeletons, Ekso Bionics develops products for both medical and industrial applications.

  3. ReWalk Robotics: Known for its robotic exoskeletons for lower limb mobility, ReWalk Robotics targets individuals with spinal cord injuries.

  4. Hocoma: A Swiss company focused on rehabilitation robotics, Hocoma offers solutions for both upper and lower limb therapy.

  5. Smaller Startups: Several startups are entering the market with innovative solutions, increasing competition and driving technological advancements.

Risk Factors

Myomo faces several risks that could impact its business operations and financial performance:

  1. Market Dependence: The company relies heavily on the success of its MyoPro® devices. Any decline in demand or competition from alternative technologies could adversely affect revenue.

  2. Regulatory Challenges: As a medical device manufacturer, Myomo must comply with stringent regulatory requirements. Delays in obtaining approvals or changes in regulations could impact product launches.

  3. Supply Chain Disruptions: The company depends on a global supply chain for components and materials. Disruptions due to geopolitical tensions, natural disasters, or pandemics could affect production.

  4. Reimbursement Risks: Changes in insurance policies or reimbursement rates could impact the affordability and accessibility of Myomo’s products.

  5. Technological Obsolescence: Rapid advancements in medical robotics could render Myomo’s products less competitive if the company fails to innovate.

Recent Developments

Myomo has made significant strides in recent years, including:

  1. New Product Launches: The company has introduced updated versions of its MyoPro® devices with enhanced features and improved performance.

  2. Telehealth Expansion: Myomo has expanded its telehealth services to reach more patients and streamline the device fitting process.

  3. Global Partnerships: The company has entered into new licensing agreements to expand its presence in international markets.

  4. COVID-19 Response: During the pandemic, Myomo adapted its operations to ensure continuity of care for patients, including the implementation of virtual consultations and remote support.

Investment Considerations

Investors considering Myomo should weigh the following factors:

Strengths

  1. Innovative Technology: Myomo’s MyoPro® devices are at the forefront of medical robotics, offering a unique solution for individuals with upper limb impairments.

  2. Growing Market: The demand for assistive technology is increasing due to an aging population and rising prevalence of neurological conditions.

  3. Strong Leadership: The company’s experienced management team is well-positioned to drive growth and innovation.

  4. Global Expansion: Myomo’s international partnerships provide access to new markets and revenue streams.

Risks

  1. High Competition: The medical robotics market is highly competitive, with several established players and new entrants.

  2. Regulatory Hurdles: Compliance with medical device regulations can be time-consuming and costly.

  3. Financial Performance: As a growing company, Myomo may face challenges in achieving consistent profitability.

Conclusion

Myomo, Inc. is a leader in the field of medical robotics, offering innovative solutions to improve mobility and quality of life for individuals with neuromuscular impairments. With a strong product portfolio, a commitment to innovation, and a focus on global expansion, the company is well-positioned for future growth. However, investors should carefully consider the risks associated with market competition, regulatory challenges, and financial performance. Overall, Myomo represents a compelling opportunity in the rapidly evolving field of assistive technology.